Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03327467|
Expanded Access Status : Available
First Posted : October 31, 2017
Last Update Posted : November 24, 2020
The objective of the study is to enable access to sibling or autologous umbilical cord blood (UCB) infusions for children with various brain disorders.
The use of UCB in this fashion is based on safety and efficacy data from prior and ongoing clinical trials at Duke University Medical Center in over 700 patients with these diagnoses infused with autologous or sibling UCB over the past decade.
|Condition or disease||Intervention/treatment|
|Autism Spectrum Disorder Autism Cerebral Palsy Hydrocephalus Apraxia of Speech Hypoxia Ischemia, Cerebral Drowning; Anoxia||Biological: Cord Blood Infusion|
The primary purpose of this protocol is to enable access to sibling or autologous umbilical cord blood for children with various brain disorders. Children with autism, apraxia, cerebral palsy, hydrocephalus, hypoxic brain injury, stroke, and other brain injuries will be eligible if they do not qualify for or are unable to participate in another active clinical trial at Duke. Children with qualifying partially or fully matched sibling or autologous cord blood units will be eligible. The family will be enrolled on the screening protocol, "A Research Database and Screening Protocol for Children with Brain Injuries Potentially Undergoing Cellular Therapy or Other Clinical Trials," Pro00063563. Information may be obtained under this protocol including but not limited to: diagnostic information, genetic testing, videos and pictures of the child, cord blood report, etc. The PI or her designee will review this information to determine if the child might be eligible for a cord blood infusion(s) on this expanded access protocol.
If eligible, the child must come to Duke with a parent or legal guardian for clinical evaluations and infusion of the umbilical cord blood unit. Parents will be required to participate in remote follow-up phone calls and be willing to complete questionnaires for safety follow-up.
|Study Type :||Expanded Access|
|Expanded Access Type :||Treatment IND/Protocol|
|Official Title:||Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries|
- Biological: Cord Blood Infusion
IV infusion of umbilical cord infusion (sibling or autologous)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03327467
|Contact: Lettie Mooreemail@example.com|
|Contact: Jayne Cashfirstname.lastname@example.org|
|United States, North Carolina|
|Duke University Medical Center||Available|
|Durham, North Carolina, United States, 27705|
|Contact: Lettie Moore email@example.com|
|Contact: Jayne Cash firstname.lastname@example.org|
|United States, Texas|
|Houston, Texas, United States, 77030|
|Contact: Silvia Saenz PediatricCellTherapy@mdanderson.org|
|Principal Investigator: Kris Mahadeo, MD|
|Principal Investigator:||Joanne Kurtzberg||Duke University|
|Principal Investigator:||Jessica Sun||Duke University|